ResMed Inc.

Valuation Analysis

About the Company

ResMed Inc. en bref

ResMed Inc. (RMD) is currently trading at 164,65 € with a market capitalization of 23,9 Md €. The trailing P/E ratio stands at 18.18x, with a forward P/E of 15.57x. The 52-week range spans from 157,32 € to 256,40 €; the current price is 35.8% below the yearly high. Year-over-year revenue growth stands at +10.8%. The net profit margin stands at 27.44%.

💰 Dividende

ResMed Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent ResMed Inc. (RMD) au consensus : Acheter. L'objectif de cours moyen est de 232,07 €, soit un potentiel de +40.95% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 157,08 € à 283,62 €.

ResMed Inc. : la thèse d'investissement en détail

ResMed Inc. (RMD) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 10.8% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 62.18%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 25.25% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Valorisation en contexte

The PEG ratio at 1.14 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 15.57x is meaningfully below the trailing 18.18x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 40.95% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.44%).

Trading Data

Related Stocks in the Same Sector

Where can I buy ResMed Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.